Where can I find the actual financial results for Eli Lilly for Q1 2026?

The actual financial results, performance metrics, and management commentary for the quarter ended March 31, 2026, are detailed in the press release filed as Exhibit 99.1 to this 8-K filing.

What is the significance of this 8-K filing?

This 8-K filing formally announces Eli Lilly's financial results for the first quarter of 2026, fulfilling regulatory requirements for timely disclosure of material information. It directs investors to the accompanying press release for the specifics of the results.

Does this 8-K filing contain forward-looking statements or risk factors?

This specific 8-K filing primarily references a press release for financial results. While press releases often contain forward-looking statements and discussions of risks, the 8-K itself does not elaborate on these; investors should review Exhibit 99.1 for such details.

What does it mean that the information is 'furnished' and not 'filed' under Item 2.02?

Information furnished under Item 2.02, such as earnings press releases, is provided to the SEC for public dissemination but is not subject to the liability provisions of Section 18 of the Exchange Act. This means the company faces fewer legal consequences for inaccuracies in this furnished information compared to formally 'filed' information, though it is still considered important by investors.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) has filed a Current Report on Form 8-K dated April 30, 2026, to announce its financial results for the quarter ended March 31, 2026. The report primarily consists of a press release (Exhibit 99.1) detailing these financial outcomes. While the filing itself does not contain the specific financial figures or operational details, it serves as a formal notification to investors that this information has been disseminated. Investors seeking detailed insights into Lilly's performance for the first quarter of 2026 should refer to the attached press release, which is incorporated by reference into this filing.

Key Highlights

1Eli Lilly and Company (LLY) filed an 8-K on April 30, 2026, reporting its financial results for the quarter ended March 31, 2026.
2The core of the filing is Exhibit 99.1, a press release containing the detailed financial and operational results.
3This filing serves as a formal announcement of the quarterly results, in line with SEC regulations.
4Investors are directed to the press release (Exhibit 99.1) for specific financial data, performance metrics, and management commentary.
5The information furnished under Item 2.02 is not deemed 'filed' for Section 18 purposes, meaning it doesn't carry the same liability as formally filed documents but is still crucial for investor information.
6The filing also includes the standard Cover Page Interactive Data File in Inline XBRL format.

ELI LILLY & Co 8-K Report, Financial Results (Apr 30, 2026)

Summary

Key Highlights

Frequently Asked Questions